Title for MeetingAbstracts
Alphabetical listing of titles
Vaccination of pregnant cynomolgus monkeys with whole inactivated SIVmac.
Vaccination of Rhesus Macaques with HIV-1 Tat Protein.
Vaccination of seronegative volunteers with an HIV-1 env/rev DNA vaccine induces antigen-specific cellular immune responses.
Vaccination with a live retrovirus: the role of T-cell subsets.
Vaccination with Autologous Dendritic Cells Pulsed with AT-2-Inactivated Whole Virus Provides Partial Protection from Pathogenic SIV Challenge.
Vaccination with Candida albicans Cell Wall Protein and Mannoprotein Constituents Confers Protection against Disseminated Candidiasis.
Vaccination with HIV DNA induces immune responses that are boosted by protein subunit.
Vaccination with Intradermal Recombinant Hepatitis B Vaccine in Healthcare Workers Who Fail to Respond to Intramuscular Vaccination.
Vaccination with live retroviruses: the nature of the protective immune response.
Vaccination with VSV G protein exchange vectors expressing HIV env and SIV gag proteins protects rhesus macaques from challenge with highly pathogenic SHIV 89.6P.
Vaccine Clinical Trials Update.
VACCINE DESIGN STUDY IN COTE D'IVOIRE (WEST AFRICA): CROSS REACTIVE HIV-1 CLADE B CD8+ T LYMPHOCYTES IN PATIENTS INFECTED WITH HIV-1 SUBTYPE CRF02-AG.
Vaccine development.
Vaccine evaluation studies of replication-defective SIV(sm)B7.
Vaccine evaluation studies of replication-defective SIVsmB7.
Vaccine induced antibodies to native HIV-1 GP120 measured by flow cytometry.
Vaccine induced CTL activity correlates with resistant phenotype in an in vitro challenge system.
Vaccine induced in vitro protective immunity against TCLA and macrophage tropic HIV.
Vaccine induction of SIVmac GAG-specific cytotoxic T lymphocytes in rhesus monkeys.
Vaccine Protection against Functional Cytotoxic T Lymphocyte Abnormalities in Simian Human Immunodeficiency Virus-Infected Rhesus Monkeys.
Vaccine protection against simian and feline immunodeficiency viruses.
Vaccine protection against simian immunodeficiency virus infection.
Vaccine protection against SIV infection in macaques.
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.
Vaccine protection from SIV infected cell challenge is MHC class I related.
Vaccine protection of rhesus macaques against SIVmac infection by high but not low doses of inactivated whole SIVmac immunogen.
Vaccine R and D priorities for travel medicine.
Vaccine Strategies for the Induction of Neutralizing Antibodies and Cellular Immune Responses against HIV-1 Subtype C Strains.
Vaccine studies in rhesus macaques using whole inactivated SIVMAC immunogen.
Vaccine trials and tribulations: regulatory discretion and ethical choices in testing candidate vaccines.